메뉴 건너뛰기




Volumn 6, Issue 3, 2011, Pages 639-640

First case of A859T epidermal growth factor receptor mutation responding to erlotinib

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PEMETREXED;

EID: 79951755469     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182037c0c     Document Type: Article
Times cited : (6)

References (6)
  • 1
    • 69949186250 scopus 로고    scopus 로고
    • Screening for epidermal growth factor receptor mutations in lung cancer
    • Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-967.
    • (2009) N. Engl. J. Med. , vol.361 , pp. 958-967
    • Rosell, R.1    Moran, T.2    Queralt, C.3
  • 2
    • 69949162760 scopus 로고    scopus 로고
    • Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma
    • Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
    • (2009) N. Engl. J. Med. , vol.361 , pp. 947-957
    • Mok, T.S.1    Wu, Y.L.2    Thongprasert, S.3
  • 3
    • 54049122600 scopus 로고    scopus 로고
    • Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations
    • Avizienyte E, Ward RA, Garner AP. Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations. Biochem J 2008;415: 197-206.
    • (2008) Biochem. J. , vol.415 , pp. 197-206
    • Avizienyte, E.1    Ward, R.A.2    Garner, A.P.3
  • 4
    • 20244389188 scopus 로고    scopus 로고
    • Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib
    • Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005;23:2493-2501.
    • (2005) J. Clin Oncol. , vol.23 , pp. 2493-2501
    • Han, S.W.1    Kim, T.Y.2    Hwang, P.G.3
  • 5
    • 33745057881 scopus 로고    scopus 로고
    • HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer [15]
    • DOI 10.1056/NEJMc060020
    • Cappuzzo F, Bemis L, Varella-Garcia M. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med 2006;354:2619-2621. (Pubitemid 43882374)
    • (2006) New England Journal of Medicine , vol.354 , Issue.24 , pp. 2619-2621
    • Cappuzzo, F.1    Bemis, L.2    Varella-Garcia, M.3
  • 6
    • 35949000487 scopus 로고    scopus 로고
    • Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFPtagged EGFR intracellular domain
    • de Gunst MM, Gallegos-Ruiz MI, Giaccone G, et al. Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFPtagged EGFR intracellular domain. Mol Cancer 2007;6:56.
    • (2007) Mol. Cancer , vol.6 , pp. 56
    • De Gunst, M.M.1    Gallegos-Ruiz, M.I.2    Giaccone, G.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.